Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Adlai Nortye
company
About
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs.
- 51 - 100
Highlights
Details
- Last Funding Type
- Series B
- Last Funding Money Raised
- $53M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2016
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Adlai Nortye is a global clinical-stage biopharmaceutical company focused on innovative oncology drugs, with its R&D and global clinical operation centers in both China and the United States. With a strategic emphasis on oncology, it has built a global pipeline through collaborations and internal discoveries with more than 10 drug candidates in development.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$53M
Adlai Nortye has raised a total of
$53M
in funding over 2 rounds. Their latest funding was raised on
Jun 26, 2018 from a Series B round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jun 26, 2018 | Series B | $53M | 1 | — | — | Detail |
Investors
Number of Lead Investors
Number of Investors
—
1
Adlai Nortye is funded by 1 investors.
Yahui Precision Medicine Fund
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Yahui Precision Medicine Fund
|
— | Series B |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
